Optimizing the Treatment Sequence: The Cumulative Clinical Benefit of Treatment Initiation With Deucravacitinib Versus Apremilast over 52 Weeks in Patients With Moderate to Severe Plaque Psoriasis from the POETYK PSO-1 Trial. J of Skin 2022, 6 (6), s62. https://doi.org/10.25251/skin.6.supp.62.